JAK2 and essential thrombocythemia: A further breakthrough came in 2013 with the identification of somatic insertions and deletions in exon 9 of the CALR gene, which encodes calreticulin, occurring in 20–25% of ET and PMF patients without JAK2 or MPL mutations [4,5].